Pharmaceutical Executive, Sep 1, 2006 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Sep 1, 2006
Executive Profile
Industry Audit
By Bill Trombetta
For the fifth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph's University to analyze the pharma industry's financial performance with a battery of business metrics old and new. The highlights: Two top biotechs race neck-and-neck for first place, Forest delivers another strong performance, and AstraZeneca squeezes past Johnson & Johnson and GlaxoSmithKline into the top four for the first time ever. And the winner is . . .
Features
Slow Deal Flow?
By Nick Rogerson , Andrea Lauber
Roche, Johnson & Johnson, and Teva have demonstrated formidable deal making for many years. But generally, business development capabilities in the pharma industry remain very patchy, with the number of poor performers far out-weighing the good.
Sewing Up New Sales
By David N. Stievater , Alexander Petersen , Rahul Bhatia
More than high-call frequency will be necessary to succeed in an increasingly competitive sales environment.
Benchmarking AIDS
By Kieran Hartsough , Daniel Rosan , Lisa Sachs
Nothing reflects pharma's response to public-health crises in sharper detail than the industry's efforts to fight the AIDS epidemic.
Freedom of Information
By Beth Herskovits
The suit draws a comparison to the newspaper industry: Even though papers profit from disseminating information, the information in question isn't commercial.
Pharm Exec Q&A: A Soft Spot for Whistleblowers
By Jill Wechsler
If I ran the FDA, I'd have a Rose Garden ceremony for all the histleblowers in my agency. No one can know where all the skeletons are buried. We ought to honor every one of those patriots.
Public Access
By Mark Bard
When people ask how health seekers look and act on the Web, there's no one answer: The online universe has become just as diverse as the rest of the world. Nowhere is this more evident than in the latest e-health statistics that, when taken together, paint a picture of customers who are beginning to find their feet—and new finesse—online.
Washington Report
Washington Report: New Partnerships Pursue Old Diseases
By Jill Wechsler
The PPP approach asks pharma to identify promising drugs and conduct pre-clinical tests, instead of paying for costly late-stage clinical trials.
From the Editor
From the Editor: Undecided
By Patrick Clinton
The world according to New Hampshire: Doctors prescribe expensive drugs because pharma reps sell them. Interfere with the selling, and you'll cut down on the prescribing. It's a plan. But for what?
Global Report
Global Report: Break with Tradition
By Sarah Houlton
Public revulsion at animal-rights extremists is damaging their cause. The majority of people deem the worst offenders to be terrorists.
Leadership
Leadership: Living to be 100
By Sander A. Flaum
Advice for new leaders: Forget the irrelevant meetings, the 300 e-mails, and the 50 voicemails.
Legal
Legal: Authorized Generics: Still Legal—and Holding
By Robert P. Reznick , James B. Kobak, Jr.
Indeed, at this time, we are aware of no evidence that the practice of authorized generics has actually deterred any Paragraph IV certification or post-180 day generic entry, let alone a challenge to an invalid patent.
Column
The Information Diet
By Richard B. Vanderveer
Physicians seek point-of-care info and updates in friendly formats. Data should be available when and how they need it, and in exactly the right amounts.
Alternative Media: The Download on Podcasting
By Scott Burkette
Electronic continuing medical education is one area that is primed for podcasting penetration.
Marketing to Professionals: Savvy Strategists
By Eleanor O'Rangers
These "guns for hire" bring the science and marketing savvy that clients need, often with in-depth category experience, but without the commitment and cost associated with hiring a full-time employee.
Sales Management: Palm-sized Payoff
By John Ryder
In a survey of 2,800 medical professionals, 88 percent reported increased efficiencies in their practices using PDA softare.
Direct to Consumer: No-Name Opportunity
By Jeannette Park
Most DTC marketers say education has been their primary goal all along, but that often, branded messages got in the way. Now marketers are doing something about it, as evidenced by recent increases in unbranded ads. Pharma companies are producing campaigns that more clearly encourage consumers to seek information about their conditions, rather than just running out and requesting a script from their doctors.
Finance
Finance: Good Alternatives
The extra cash validated for equity investors that Acorda could go out and market Zanaflex.
Thought Leader
Thoughtleader: Small Cost, Big Win
Just because outside contractors and vendors are experts does not mean everything will happen exactly the way you want it to. There's a lot of oversight.
India
Inda: An Emerging Knowledge Superpower
By Frederic Chouraki

ADVERTISEMENT

Click here